Financials United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 19/07/2024 BST 5-day change 1st Jan Change
329.2 USD +0.15% Intraday chart for United Therapeutics Corporation +2.42% +49.69%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,865 6,746 9,731 12,674 10,333 14,604 - -
Enterprise Value (EV) 1 3,977 5,711 9,637 12,513 8,039 12,367 11,238 10,110
P/E ratio -36.9 x 13.2 x 21.5 x 18.5 x 11.1 x 13.4 x 12.2 x 12.3 x
Yield - - - - - - - -
Capitalization / Revenue 2.67 x 4.55 x 5.77 x 6.55 x 4.44 x 5.32 x 4.9 x 4.63 x
EV / Revenue 2.74 x 3.85 x 5.72 x 6.46 x 3.45 x 4.5 x 3.77 x 3.21 x
EV / EBITDA -28.1 x 8.87 x 15.9 x 12.1 x 6.49 x 8.6 x 7.48 x 6.73 x
EV / FCF -13.7 x 8.2 x 20.2 x 18.9 x 10.8 x 11.5 x 10.1 x 7.38 x
FCF Yield -7.3% 12.2% 4.95% 5.3% 9.3% 8.68% 9.94% 13.5%
Price to Book 1.39 x 1.99 x 2.67 x 2.67 x 1.73 x 2.12 x 1.8 x 1.58 x
Nbr of stocks (in thousands) 43,881 44,441 45,037 45,577 46,994 44,366 - -
Reference price 2 88.08 151.8 216.1 278.1 219.9 329.2 329.2 329.2
Announcement Date 26/02/20 24/02/21 24/02/22 22/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,449 1,483 1,686 1,936 2,328 2,747 2,981 3,153
EBITDA 1 -141.7 643.5 605.8 1,031 1,238 1,438 1,502 1,503
EBIT 1 -187.6 593.6 555.9 979.7 1,185 1,409 1,547 1,555
Operating Margin -12.95% 40.02% 32.98% 50.6% 50.91% 51.3% 51.87% 49.32%
Earnings before Tax (EBT) 1 -165 638.9 593.9 950.6 1,274 1,544 1,708 1,711
Net income 1 -104.5 514.8 475.8 727.3 984.8 1,190 1,300 1,302
Net margin -7.21% 34.71% 28.23% 37.56% 42.31% 43.32% 43.59% 41.31%
EPS 2 -2.390 11.54 10.06 15.00 19.81 24.65 27.02 26.77
Free Cash Flow 1 -290.3 696.4 477.4 663.7 747.6 1,073 1,118 1,369
FCF margin -20.04% 46.95% 28.32% 34.28% 32.12% 39.06% 37.48% 43.44%
FCF Conversion (EBITDA) - 108.22% 78.8% 64.37% 60.38% 74.6% 74.39% 91.13%
FCF Conversion (Net income) - 135.28% 100.34% 91.26% 75.91% 90.16% 85.99% 105.15%
Dividend per Share 2 - - - - - - - -
Announcement Date 26/02/20 24/02/21 24/02/22 22/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 415.2 461.9 466.9 516 491.5 506.9 596.5 609.4 614.7 677.7 689 707.8 705.2 795.3 840.8
EBITDA 182.4 300.5 214.5 327.2 188.8 297.7 326.3 340.3 273.8 371.3 - - - - -
EBIT 1 169.8 288 201.8 314.3 175.6 284.4 313.4 327 260.1 356.3 365.4 374.2 338 502.5 503.9
Operating Margin 40.9% 62.35% 43.22% 60.91% 35.73% 56.11% 52.54% 53.66% 42.31% 52.57% 53.04% 52.87% 47.93% 63.18% 59.93%
Earnings before Tax (EBT) 1 140.5 308.7 150.6 312.5 178.8 291.9 335.2 351.8 295.4 398.6 399.2 409.9 347.7 545.2 547.2
Net income 1 112.2 239.9 116 239.3 132.1 240.9 259.2 267.6 217.1 306.6 310.4 316.7 280.4 430.7 432.3
Net margin 27.02% 51.94% 24.84% 46.38% 26.88% 47.52% 43.45% 43.91% 35.32% 45.24% 45.05% 44.74% 39.75% 54.16% 51.41%
EPS 2 2.350 5.030 2.410 4.910 2.670 4.860 5.240 5.380 4.360 6.170 6.338 6.614 5.866 9.180 9.210
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 24/02/22 04/05/22 03/08/22 02/11/22 22/02/23 03/05/23 02/08/23 01/11/23 21/02/24 01/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 112 - - - - - - -
Net Cash position 1 - 1,035 94.8 161 2,294 2,237 3,366 4,493
Leverage (Debt/EBITDA) -0.7876 x - - - - - - -
Free Cash Flow 1 -290 696 477 664 748 1,073 1,118 1,369
ROE (net income / shareholders' equity) -3.75% 16.7% 12.9% 16.6% 18.3% 18.4% 15.9% 13.3%
ROA (Net income/ Total Assets) 15.6% 12.1% 9.85% 13% 14.9% 15.2% 14.3% 12.6%
Assets 1 -671.4 4,264 4,832 5,607 6,606 7,827 9,109 10,360
Book Value Per Share 2 63.40 76.40 81.00 104.0 127.0 155.0 182.0 209.0
Cash Flow per Share 2 -4.720 16.90 12.60 16.50 19.70 28.40 27.30 28.70
Capex 1 83.7 59.3 121 139 230 178 244 187
Capex / Sales 5.78% 4% 7.17% 7.17% 9.9% 6.46% 8.17% 5.92%
Announcement Date 26/02/20 24/02/21 24/02/22 22/02/23 21/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
329.2 USD
Average target price
314.9 USD
Spread / Average Target
-4.32%
Consensus
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. Financials United Therapeutics Corporation